Evolving data continue to require pathologists to adjust breast cancer biomarker interpretation and reporting. ER low positive and HER2 low/ultralow are not distinct subtypes of breast cancer but have important treatment implications. ER low positive (1%-10%) ... ...

请注册登录后继续浏览